Amifostine every-other-day regimen + Amifostine everyday regimen
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Neoplasms
Conditions
Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases, Mucositis
Trial Timeline
Jan 1, 2013 → Dec 1, 2019
NCT ID
NCT01762514About Amifostine every-other-day regimen + Amifostine everyday regimen
Amifostine every-other-day regimen + Amifostine everyday regimen is a phase 2 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Neoplasms. The current trial status is unknown. This product is registered under clinical trial identifier NCT01762514. Target conditions include Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases.
What happened to similar drugs?
0 of 13 similar drugs in Nasopharyngeal Neoplasms were approved
Approved (0) Terminated (0) Active (13)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01762514 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Nasopharyngeal Neoplasms